Horizon Therapeutics Public (HZNP) Stock Price, News & Analysis

Company Overview

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Key Stats

• Today's Range: $116.30 to $116.30
• 50-Day Range: $112.60 to $116.30
• 52-Week Range: $60.03 to $116.38
• Volume: N/A
• Average Volume: 2.50 million shs
• Market Capitalization: $26.63 billion
• P/E Ratio: 62.19
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Horizon Therapeutics Public Stock Analysis - MarketRank™

Horizon Therapeutics Public scored higher than 42% of companies evaluated by MarketBeat, and ranked 694th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Horizon Therapeutics Public.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 35.08%

Earnings Growth

Earnings for Horizon Therapeutics Public are expected to grow by 35.08% in the coming year, from $4.19 to $5.66 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Horizon Therapeutics Public is 62.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 124.79.

Price to Earnings Ratio vs. Sector

The P/E ratio of Horizon Therapeutics Public is 62.19, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.02.

Price to Earnings Growth Ratio

Horizon Therapeutics Public has a PEG Ratio of 3.96. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Horizon Therapeutics Public has a P/B Ratio of 5.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for HZNP.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Horizon Therapeutics Public does not currently pay a dividend.

Dividend Growth

Horizon Therapeutics Public does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.2 / 5
• Environmental Score: -2.61

Short Interest

There is no current short interest data available for HZNP.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

23 people have searched for HZNP on MarketBeat in the last 30 days. This is an increase of 475% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Horizon Therapeutics Public insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.20% of the stock of Horizon Therapeutics Public is held by insiders.

Percentage Held by Institutions

80.37% of the stock of Horizon Therapeutics Public is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HZNP Stock Analysis - Frequently Asked Questions

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported $1.20 EPS for the quarter, topping analysts' consensus estimates of $1.12 by $0.08. Horizon Therapeutics Public's quarterly revenue was up 7.8% on a year-over-year basis.

Does Horizon Therapeutics Public have any subsidiaries?

Horizon Therapeutics Public subsidiaries include Viela Bio Inc., Curzion Pharmaceuticals Inc., River Vision Development Corp., Raptor Pharmaceuticals, Hyperion Therapeutics, Vidara Therapeutics, Horizon Medicines LLC, and more.

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Horizon Therapeutics Public investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), PayPal (PYPL), Tesla (TSLA), Netflix (NFLX) and Bristol-Myers Squibb (bmy).

Company Calendar

• Last Earnings: 8/08/2023
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:HZNP
• CUSIP: 44047T10
• CIK: 1492426
• Web: www.horizontherapeutics.com
• Phone: (531) 772-2100
• Fax: 224-383-3001
• Employees: 2,115
• Year Founded: 2008

Profitability

• EPS (Most Recent Fiscal Year): $1.87
• Trailing P/E Ratio: 62.19
• Forward P/E Ratio: 27.76
• P/E Growth: 3.96
• Net Income: $521.48 million
• Net Margins: 12.02%
• Pretax Margin: 12.18%
• Return on Equity: 20.46%
• Return on Assets: 11.52%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 4.27
• Quick Ratio: 4.09

Sales & Book Value

• Annual Sales: $3.63 billion
• Price / Sales: 7.34
• Cash Flow: $7.05 per share
• Price / Cash Flow: 16.49
• Book Value: $22.38 per share
• Price / Book: 5.20

Miscellaneous

• Outstanding Shares: 228,990,000
• Free Float: 223,957,000
• Market Cap: $26.63 billion
• Optionable: Optionable
• Beta: 1.03